Company: NCNA
Filing Date: 2025-04-04
Form Type: DRS
Source: 0000950123-25-003335
Chunk: 7

Company: NuCana plc
Filing Date: 2025-04-04
Form: DRS
Chunk 7
---
 inform themselves about, and to observe, any restrictions as to the offering and the distribution of
this prospectus applicable to those jurisdictions.

Unless otherwise indicated or the context otherwise requires, in this prospectus,
“NuCana,” “NuCana plc,” the “Company,” “we,” “us” and “our” refer to NuCana plc and its consolidated subsidiaries. See “Description of Share Capital.”

This prospectus and the information incorporated by reference herein and therein contains references to trademarks, trade names and service
marks belonging to us or other entities. Solely for convenience, trademarks, trade names and service marks referred to in this prospectus may appear without the or TM symbols, but such
references are not intended to indicate, in any way, that the applicable owner will not assert, to the fullest extent under applicable law, its rights to these trademarks and trade names. We do not intend our use or display of other companies’
trade names, trademarks, or service marks to imply a relationship with, or endorsement or sponsorship of us by, any other companies. All trademarks, trade names, and service marks included or incorporated by reference into this prospectus are the
property of their respective owners.

1

Confidential Treatment Requested by Nucana plc Pursuant to 17 C.F.R. Section 200.83

PROSPECTUS SUMMARY This summary highlights information contained elsewhere in this prospectus and in the documents incorporated by reference herein. It may not contain all of the information that may be important to you. Before investing in our securities, you should read this entire prospectus and information incorporated by reference into this prospectus, including the financial statements and related notes and “Risk Factors” starting on page 7 of this prospectus, carefully for a more complete understanding of our business and this offering. The Company We are a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying our ProTide ™technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid and hematological tumors, they have significant shortcomings that limit their efficacy and they are often poorly tolerated. Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome the key limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. Our pipeline includes NUC-7738